Mirum’s volixibat shows ‘best-in-class potential,’ says Citi

Citi keeps a Buy rating on Mirum Pharmaceuticals (MIRM) with a $72 price target after the company reported interim data for its Phase 2b VANTAGE study of volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis. Through 28 weeks of treatment, patients taking either 80mg or 20mg twice daily reported a placebo-adjusted 2.51-point reduction in their ItchRO scores as compared to baseline, the analyst tells investors in a research note. The firm says that while volixibat is slightly behind in clinical development, its efficacy profile “demonstrate best-in-class potential for the largely unpenetrated PBC market.”